Capricor Therapeutics Files 8-K
Ticker: CAPR · Form: 8-K · Filed: Jan 2, 2025 · CIK: 1133869
| Field | Detail |
|---|---|
| Company | Capricor Therapeutics, Inc. (CAPR) |
| Form Type | 8-K |
| Filed Date | Jan 2, 2025 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.001, $10.0 million |
| Sentiment | neutral |
Sentiment: neutral
Topics: 8-k, regulatory-filing
Related Tickers: CAPR
TL;DR
CAPR filed an 8-K on Jan 2, 2025 - mostly procedural filings.
AI Summary
On January 2, 2025, Capricor Therapeutics, Inc. filed an 8-K report. The filing primarily concerns other events and financial statements/exhibits, with no specific material events detailed in the provided text.
Why It Matters
This 8-K filing indicates Capricor Therapeutics, Inc. is submitting required regulatory documentation, though the specific details of 'Other Events' are not elaborated in this excerpt.
Risk Assessment
Risk Level: low — The provided text is a standard 8-K filing notification and does not contain information that would immediately suggest a high-risk event.
Key Players & Entities
- CAPRICOR THERAPEUTICS, INC. (company) — Registrant
- January 2, 2025 (date) — Date of Report
- Delaware (jurisdiction) — State of incorporation
- 001-34058 (filing_id) — Commission File Number
- 88-0363465 (tax_id) — I.R.S. Employer Identification No.
- 10865 Road to the Cure, Suite 150, San Diego, California (address) — Principal executive offices
FAQ
What is the primary purpose of this 8-K filing?
The filing is a Current Report Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934, reporting 'Other Events' and 'Financial Statements and Exhibits'.
When was this 8-K filed?
The filing was made on January 2, 2025.
What is Capricor Therapeutics, Inc.'s state of incorporation?
Capricor Therapeutics, Inc. is incorporated in Delaware.
What is the Commission File Number for Capricor Therapeutics, Inc.?
The Commission File Number is 001-34058.
Where are Capricor Therapeutics, Inc.'s principal executive offices located?
The principal executive offices are located at 10865 Road to the Cure, Suite 150, San Diego, California.
Filing Stats: 518 words · 2 min read · ~2 pages · Grade level 10.2 · Accepted 2025-01-02 14:17:58
Key Financial Figures
- $0.001 — h Registered Common Stock, par value $0.001 per share CAPR The Nasdaq Capital M
- $10.0 million — on has triggered a milestone payment of $10.0 million from Nippon Shinyaku payable to the Com
Filing Documents
- capr-20250102x8k.htm (8-K) — 38KB
- capr-20250102xex99d1.htm (EX-99.1) — 16KB
- capr-20250102xex99d1001.jpg (GRAPHIC) — 5KB
- 0001558370-25-000010.txt ( ) — 181KB
- capr-20250102.xsd (EX-101.SCH) — 3KB
- capr-20250102_lab.xml (EX-101.LAB) — 15KB
- capr-20250102_pre.xml (EX-101.PRE) — 9KB
- capr-20250102x8k_htm.xml (XML) — 5KB
01 Other Events
Item 8.01 Other Events. On January 2, 2025, Capricor Therapeutics, Inc. (the "Company" or "Capricor") issued a press release announcing that it has completed the submission of its Biologics License Application ("BLA") to the U.S. Food and Drug Administration ("FDA") seeking full approval for deramiocel, an investigational cell therapy, to treat patients diagnosed with Duchenne muscular dystrophy ("DMD") cardiomyopathy. Additionally, the Company announced that the completion of the BLA submission has triggered a milestone payment of $10.0 million from Nippon Shinyaku payable to the Company under its U.S. Exclusive Commercialization and Distribution Agreement dated January 24, 2022. A copy of the press release has been filed as Exhibit 99.1 hereto and is incorporated herein by reference.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits 99.1 Press Release, titled "Capricor Therapeutics Completes Submission of Biologics License Application to the U.S. FDA for Deramiocel for the Treatment of Duchenne Muscular Dystrophy", dated January 2, 2025. 104 Cover Page Interactive Data File (formatted as inline XBRL). 2
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized. CAPRICOR THERAPEUTICS, INC. Date: January 2, 2025 By: /s/ Linda Marbn, Ph.D. Linda Marbn, Ph.D. Chief Executive Officer 3